For research use only
| Cat No. | ABC-X0137C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Epithelial-like |
| Species | Human |
| Host Cell | CT26 |
| Source Organ | Colon |
| Disease | Colorectal Carcinoma |
| Storage | Liquid Nitrogen |
The Xpress™ Human CD39 Overexpressing Cell Line (CT26) is an important model for researching immune tolerance and tumor microenvironment interactions.
Xpress™ Human CD39 over-expressing cell line (CT26) is a genetically engineered model derived from selected murine CT26 parental cell line based on customers’ requirement. Human CD39 overexpression cell line is generated by stable integration of exogenous human CD39 gene into CT26 host cells using our optimized transduction of lentiviral vectors. Overexpression clone is validated at gene level by qRT-PCR.
Target
CD39 (ENTPD1) is an ectonucleotidase that hydrolyzes extracellular ATP and ADP into AMP, contributing to the immunosuppressive adenosine pathway. It is widely expressed in the tumor microenvironment and associated with regulatory T cell function, immune tolerance, and poor cancer prognosis. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0137C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Colon |
| Disease | Colorectal Carcinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | CT26 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The Xpress™ Human CD39 over-expressing cell line (CT26) is a suitable model for investigating adenosine-mediated immunosuppression and for screening CD39 inhibitors. It is widely used in the development of cancer immunotherapy and metabolic pathway modulators.